These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
479 related items for PubMed ID: 16414180
21. A 3D QSAR model of 17beta-HSD1 inhibitors based on a thieno[2,3-d]pyrimidin-4(3H)-one core applying molecular dynamics simulations and ligand-protein docking. Karkola S, Lilienkampf A, Wähälä K. ChemMedChem; 2008 Mar; 3(3):461-72. PubMed ID: 18224704 [Abstract] [Full Text] [Related]
22. Substituted 6-phenyl-2-naphthols. Potent and selective nonsteroidal inhibitors of 17beta-hydroxysteroid dehydrogenase type 1 (17beta-HSD1): design, synthesis, biological evaluation, and pharmacokinetics. Marchais-Oberwinkler S, Kruchten P, Frotscher M, Ziegler E, Neugebauer A, Bhoga U, Bey E, Müller-Vieira U, Messinger J, Thole H, Hartmann RW. J Med Chem; 2008 Aug 14; 51(15):4685-98. PubMed ID: 18630892 [Abstract] [Full Text] [Related]
24. Bicyclic substituted hydroxyphenylmethanones as novel inhibitors of 17β-hydroxysteroid dehydrogenase type 1 (17β-HSD1) for the treatment of estrogen-dependent diseases. Oster A, Hinsberger S, Werth R, Marchais-Oberwinkler S, Frotscher M, Hartmann RW. J Med Chem; 2010 Nov 25; 53(22):8176-86. PubMed ID: 20977238 [Abstract] [Full Text] [Related]
25. Estrone and estradiol C-16 derivatives as inhibitors of type 1 17beta-hydroxysteroid dehydrogenase. Poirier D, Chang HJ, Azzi A, Boivin RP, Lin SX. Mol Cell Endocrinol; 2006 Mar 27; 248(1-2):236-8. PubMed ID: 16337735 [Abstract] [Full Text] [Related]
26. 17beta-hydroxysteroid dehydrogenase Type 1, and not Type 12, is a target for endocrine therapy of hormone-dependent breast cancer. Day JM, Foster PA, Tutill HJ, Parsons MF, Newman SP, Chander SK, Allan GM, Lawrence HR, Vicker N, Potter BV, Reed MJ, Purohit A. Int J Cancer; 2008 May 01; 122(9):1931-40. PubMed ID: 18183589 [Abstract] [Full Text] [Related]
27. A new nonestrogenic steroidal inhibitor of 17β-hydroxysteroid dehydrogenase type I blocks the estrogen-dependent breast cancer tumor growth induced by estrone. Ayan D, Maltais R, Roy J, Poirier D. Mol Cancer Ther; 2012 Oct 01; 11(10):2096-104. PubMed ID: 22914440 [Abstract] [Full Text] [Related]
28. Chemical synthesis, characterisation and biological evaluation of furanic-estradiol derivatives as inhibitors of 17β-hydroxysteroid dehydrogenase type 1. Farhane S, Laplante Y, Poirier D. Med Chem; 2011 Mar 01; 7(2):80-91. PubMed ID: 21222612 [Abstract] [Full Text] [Related]
30. Design, synthesis, biological evaluation and pharmacokinetics of bis(hydroxyphenyl) substituted azoles, thiophenes, benzenes, and aza-benzenes as potent and selective nonsteroidal inhibitors of 17beta-hydroxysteroid dehydrogenase type 1 (17beta-HSD1). Bey E, Marchais-Oberwinkler S, Werth R, Negri M, Al-Soud YA, Kruchten P, Oster A, Frotscher M, Birk B, Hartmann RW. J Med Chem; 2008 Nov 13; 51(21):6725-39. PubMed ID: 18855374 [Abstract] [Full Text] [Related]
31. Chemical synthesis, characterisation and biological evaluation of lactonic-estradiol derivatives as inhibitors of 17β-hydroxysteroid dehydrogenase type 1. Farhane S, Fournier MA, Poirier D. J Steroid Biochem Mol Biol; 2013 Sep 13; 137():322-31. PubMed ID: 23685015 [Abstract] [Full Text] [Related]
33. C6-(N,N-butyl-methyl-heptanamide) derivatives of estrone and estradiol as inhibitors of type 1 17beta-hydroxysteroid dehydrogenase: Chemical synthesis and biological evaluation. Cadot C, Laplante Y, Kamal F, Luu-The V, Poirier D. Bioorg Med Chem; 2007 Jan 15; 15(2):714-26. PubMed ID: 17110114 [Abstract] [Full Text] [Related]
34. Chemical Synthesis and Biological Evaluation of 3-Substituted Estrone/Estradiol Derivatives as 17β-Hydroxysteroid Dehydrogenase Type 1 Inhibitors Acting via a Reverse Orientation of the Natural Substrate Estrone. Ngueta AD, Roy J, Maltais R, Poirier D. Molecules; 2023 Jan 07; 28(2):. PubMed ID: 36677690 [Abstract] [Full Text] [Related]
35. Novel and potent 17beta-hydroxysteroid dehydrogenase type 1 inhibitors. Lawrence HR, Vicker N, Allan GM, Smith A, Mahon MF, Tutill HJ, Purohit A, Reed MJ, Potter BV. J Med Chem; 2005 Apr 21; 48(8):2759-62. PubMed ID: 15828812 [Abstract] [Full Text] [Related]
36. Triazole ring-opening leads to the discovery of potent nonsteroidal 17β-hydroxysteroid dehydrogenase type 2 inhibitors. Xu K, Al-Soud YA, Wetzel M, Hartmann RW, Marchais-Oberwinkler S. Eur J Med Chem; 2011 Dec 21; 46(12):5978-90. PubMed ID: 22037253 [Abstract] [Full Text] [Related]
37. Mammalian lignans and genistein decrease the activities of aromatase and 17beta-hydroxysteroid dehydrogenase in MCF-7 cells. Brooks JD, Thompson LU. J Steroid Biochem Mol Biol; 2005 Apr 21; 94(5):461-7. PubMed ID: 15876411 [Abstract] [Full Text] [Related]
38. Effects of Org OD14 (Livial) and its metabolites on 17 beta-hydroxysteroid dehydrogenase activity in hormone-dependent MCF-7 and T-47D breast cancer cells. Chetrite GS, Kloosterboer HJ, Philippe JC, Pasqualini JR. Anticancer Res; 1999 Apr 21; 19(1A):261-7. PubMed ID: 10226552 [Abstract] [Full Text] [Related]
39. Novel estrone mimetics with high 17beta-HSD1 inhibitory activity. Oster A, Klein T, Werth R, Kruchten P, Bey E, Negri M, Marchais-Oberwinkler S, Frotscher M, Hartmann RW. Bioorg Med Chem; 2010 May 15; 18(10):3494-505. PubMed ID: 20413314 [Abstract] [Full Text] [Related]
40. Recent insight on the control of enzymes involved in estrogen formation and transformation in human breast cancer. Pasqualini JR, Chetrite GS. J Steroid Biochem Mol Biol; 2005 Feb 15; 93(2-5):221-36. PubMed ID: 15860265 [Abstract] [Full Text] [Related] Page: [Previous] [Next] [New Search]